Bevasiranib sodium
Based on 1 Customer Validation
Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration.
For research use only. We do not sell to patients.
- Purity : 97.99%
- CAS No.: 849758-52-7
- Molecular Weight:13345.2 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All VEGFR Isoforms
More
Biological Activity
Description
In Vivo
Bevasiranib (70-350 µg; intravitreal injection; 3 doses) sodium reduces CNV area by more than 50% in a dose-dependent manner and alleviates vascular leakage in a laser-induced CNV monkey model[1].
Bevasiranib (0.5-2 mg; intravitreal injection; single dose) sodium achieves extensive ocular distribution in rabbits and results in substantial accumulation of the intact compound in the retinal pigment epithelium-Bruch's membrane complex[1].
Bevasiranib (0.5-2.0 mg/eye; intravitreal administration; single bolus dose) sodium achieves broad ocular distribution and substantial and sustained uptake in the retina in Dutch Belted rabbits[2].
Bevasiranib (2 mg/eye; intravitreal; single bolus dose) sodium delivers intact siRNA to multiple ocular tissues, including the retina and RPE, in male Dutch Belted rabbits, with RPE levels ranging from 423 ng to 2696 ng per eye[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 849758-52-7
-
Appearance Solid
-
Molecular Weight 13345.2 (free acid)
-
Color White to off-white
-
SMILES
[Bevasiranib (sodium)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Garba AO, et al. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmology and eye diseases. 2010;2:75-83. [Content Brief]
[2]. Dejneka NS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Molecular vision. 2008 May 28;14:997-1005. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)